Helix BioPharma Corp., a clinical-stage oncology company, announced the voting results from its Annual General and Special Meeting held on January 30, 2026. Shareholders voted overwhelmingly in favor of all items of business, with 99.99% approval on each resolution. A total of 61,885,815 common shares were voted, representing 81.03% of the company's total issued and outstanding shares.
The four director nominees listed in the Management Information Circular dated December 15, 2025, were re-elected to hold office for the ensuing year. The directors re-elected are Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube. Each received over 99.99% votes in favor, with only a negligible number of votes withheld.
Shareholders also approved the appointment of Clearhouse LLP as auditor of Helix BioPharma until the next annual general meeting, with remuneration to be determined by the directors. The resolution was passed with 99.99% of votes cast in favor.
A significant item on the agenda was the approval of an amendment to the company's articles to effect a consolidation of issued and outstanding common shares. The consolidation ratio can be up to five pre-consolidation shares for one post-consolidation share, with the board authorized to determine the final ratio at its sole discretion. This resolution also received 99.99% approval from shareholders.
The high voter turnout and near-unanimous approval reflect strong shareholder confidence in Helix BioPharma's leadership and strategic plans. The share consolidation is intended to potentially increase the marketability and liquidity of the company's shares. Further details on all items voted at the meeting will be filed on SEDAR+ at www.sedarplus.com.
Helix BioPharma is a clinical-stage oncology company focused on developing novel therapies for hard-to-treat cancers. Its pipeline includes a proprietary technology platform of bio-conjugates targeting CEACAM6-expressing solid tumors. The lead candidate, Tumour Defence Breaker™ L-DOS47, is an antibody-enzyme conjugate that has completed Phase Ib studies in non-small cell lung cancer. The company is listed on the TSX under the symbol "HBP", on OTC PINK under "HBPCF", and on FWB under "HBP0". For more information, visit https://www.helixbiopharma.com/.
This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially. For more information on risk factors, refer to the company's filings on SEDAR+.
